Heparin-induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation

Brigitte Tardy-Poncet, Emmanuel de Maistre, Claire Pouplard, Emilie Presles, Martine Alhenc-Gelas, Dominique Lasne, Marie-Hélène Horellou, Christine Mouton, Anne Serre-Sapin, Anne Bauters, Philippe Nguyen, François Mullier, Julien Perrin, Grégoire Le Gal, Pierre-Emmanuel Morange, Lélia Grunebaum, Agnès Lillo-Le Louet, Ismail Elalamy, Yves Gruel, Andreas Greinacher, Thomas Lecompte, Bernard Tardy, GFHT-HIT study group, Brigitte Tardy-Poncet, Emmanuel de Maistre, Claire Pouplard, Emilie Presles, Martine Alhenc-Gelas, Dominique Lasne, Marie-Hélène Horellou, Christine Mouton, Anne Serre-Sapin, Anne Bauters, Philippe Nguyen, François Mullier, Julien Perrin, Grégoire Le Gal, Pierre-Emmanuel Morange, Lélia Grunebaum, Agnès Lillo-Le Louet, Ismail Elalamy, Yves Gruel, Andreas Greinacher, Thomas Lecompte, Bernard Tardy, GFHT-HIT study group

Abstract

Background: Diagnosis of heparin-induced thrombocytopenia (HIT) requires pretest probability assessment and dedicated laboratory assays.

Objective: To develop a pretest score for HIT.

Design: Observational; analysis of prospectively collected data of hospitalized patients suspected with HIT (ClinicalTrials.gov NCT00748839).

Setting: Thirty-one tertiary hospitals in France, Switzerland, and Belgium.

Patients: Patients tested for HIT antibodies (2280 evaluable), randomly allocated to derivation and validation cohorts.

Measurements: Independent adjudicators diagnosed HIT based on the prospectively collected data and serotonin release assay results.

Results: Heparin-induced thrombocytopenia was diagnosed in 234 (14.7%) and 99 (14.5%) patients in the two cohorts. Eight features were associated with HIT (in brackets, points assigned for score calculation of the score): unfractionated heparin (1); therapeutic-dose heparin (1); cardiopulmonary bypass (cardiac surgery) (2); major trauma (3); 5- to 21-day interval from anticoagulation initiation to suspicion of HIT (4); ≥40% decrease in platelet count over ≤6 days (3); thrombotic event, arterial (3) or venous (3). The C-statistic was 0.79 (95% CI, 0.76-0.82). In the validation cohort, the area under the receiver operating characteristic curve was 0.77 (95% CI, 0.74-0.80). Three groups of scores were defined; HIT prevalence reached almost 30% in the high-probability group.

Limitation: The performance of the score may depend on settings and practices.

Conclusion: The objective, easy-to-collect, clinical features of HIT we evidenced were incorporated into a pretest score, which may guide clinical decisions regarding diagnostic testing and anticoagulation.

Keywords: heparin; heparin-induced thrombocytopenia; observational study; pre-test score; thrombocytopenia.

© 2021 International Society on Thrombosis and Haemostasis.

References

REFERENCES

    1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
    1. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
    1. McKenzie SE, Sachais BS. Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol. 2014;21:380-387.
    1. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2:3360-3392.
    1. Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost. 2007;98:1357-1361.
    1. Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127:546-557.
    1. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol. 2015;90:564-572.
    1. Tardy B, Presles E, Akrour M, de Maistre E, Lecompte T, Tardy-Poncet B. Experts’ opinion or the serotonin release assay as a gold standard for the diagnosis of heparin-induced thrombocytopenia (HIT)? J Thromb Haemost. 2011;9:1667-1669.
    1. Pandya KA, Johnson EG, Davis GA, Padmanabhan A. Serotonin release assay (SRA)-negative HIT, a newly recognized entity: Implications for diagnosis and management. Thromb Res. 2018;172:169-171.
    1. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 3rd ed. New York, NY: Marcel Dekker Inc; 2004;53-106.
    1. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
    1. Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2004;2:1882-1888.
    1. Cuker A, Arepally G, Crowther MA, et al. The HIT expert probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8:2642-2650.
    1. Pouplard C, Guéret P, Fouassier M, et al. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2007;5:1373-1379.
    1. Bryant A, Low J, Austin S, Joseph JE. Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol. 2008;143:721-726.
    1. Tawfik NM, Hegazy MA, Hassan EA, Ramadan YK, Nasr AS. Egyptian experience of reliability of 4T's score in diagnosis of heparin induced thrombocytopenia syndrome. Blood Coagul Fibrinolysis. 2011;22:701-705.
    1. Joseph L, Gomes MP, Al Solaiman F, et al. External validation of the HIT expert probability (HEP) score. Thromb Haemost. 2015;113:633-640.
    1. Pishko AM, Fardin S, Lefler DS, et al. Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Adv. 2018;2:3155-3162.
    1. Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7:1260-1265.
    1. Nellen V, Sulzer I, Barizzi G, Lämmle B, Alberio L. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica. 2012;97:89-97.
    1. Linkins LA, Bates SM, Lee AY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015;126:597-603.
    1. Din F, Kovacs MJ, Butler R, Lazo-Langner A. Inter-observer variability in the assessment of the 4TS score for the diagnosis of heparin-induced thrombocytopenia in patients undergoing cardiac surgery. Blood. 2009;114:Abstract 4467.
    1. Nagler M, Fabbro T, Wuillemin WA. Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia. J Thromb Haemost. 2012;10:151-152.
    1. Strutt JK, Mackey JE, Johnson SM, Sylvia LM. Assessment of the 4Ts pretest clinical scoring system as a predictor of heparin-induced thrombocytopenia. Pharmacotherapy. 2011;31:138-145.
    1. Harbrecht U, Bastians B, Kredteck A, Hanfland P, Klockgether T, Pohl C. Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology. 2004;62:657-659.
    1. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131:1644-1649.
    1. Martel L, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin: a meta-analysis. Blood. 2005;106:2710-2715.
    1. Bidet A, Tardy-Poncet B, Desprez D, et al. GEHT-HIT study group. Clinical characteristics and laboratory testing of patients with suspected HIT: a survey on current practice in 11 university hospitals in France. Thromb Res. 2010;125:294-299.
    1. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
    1. Hendrickson JMT, Geersing GJ, Moons GM, de Groot AH. Diagnostic and prognostic prediction models. J Thromb Haemost. 2013;11:129-141.
    1. Gruel Y, Vayne C, Rollin J, et al. Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature. Thromb Haemost. 2020;120:1096-1107.
    1. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129:2864-2872.
    1. Dhakal B, Kreuziger LB, Rein L, et al. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol. 2018;5:e220-e231.
    1. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
    1. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010;115:1797-1803.
    1. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003;121:786-792.
    1. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program. 2006;2006(1):408-414.
    1. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol. 2005;128:837-841.
    1. Warkentin TE. HIT as a preventable disease. Blood. 2005;106:2600.
    1. Lefler DS, Cuker A, Linkins LA, Warkentin TE, Pishko AM. Maximum 24-hour platelet count fall: Metric for improving the diagnosis of heparin-induced thrombocytopenia among patients with intermediate probability 4Ts scores. J Thromb Haemost. 2020;18:2018-2024.
    1. Rice L. There is no such thing as a "positive" antibody test: diagnosing heparin-induced thrombocytopenia in 2015. Chest. 2015;148:1-3.
    1. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160-4167.
    1. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost. 2010;8:30-36.
    1. Raschke RA, Gallo T, Curry SC, et al. Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15:1640-1645.
    1. Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia. J Clin Med. 2020;9:1226.
    1. Motohashi S, Matsuo T, Inoue H, Kaneko M, Shindo S. Clinical significance of the serotonin release assay and platelet count monitoring after cardiac surgery. Clin Appl Thromb Hemost. 2018;24:944-949.
    1. Moore JC, Arnold DM, Warkentin TE, Warkentin AE, Kelton JG. An algorithm for resolving ‘indeterminate’ test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. J Thromb Haemost. 2008;6:1595-1597.
    1. East JM, Cserti-Gazdewich CM, Granton JT. Heparin-induced thrombocytopenia in the critically ill patient. Chest. 2018;154:678-690.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다